Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ARQL > SEC Filings for ARQL > Form 8-K on 30-Oct-2012All Recent SEC Filings

Show all filings for ARQULE INC

Form 8-K for ARQULE INC


Other Events

Item 8.01 Other Events.

ArQule, Inc. ("ArQule" or the "Registrant") reports that Hakko Kirin Co., Ltd. ("Kyowa"), which has licensed from ArQule exclusive development rights to tivantinib in Japan and certain parts of Asia, has today issued a press release related to the discontinuation of its ongoing Phase 3 ATTENTION (Asian Trial of Tivantinib plus Erlotinib for NSCLC without EGFR Mutation) trial based on a recommendation by the trial's Safety Review Committee. This study is a randomized, double-blinded trial comparing tivantinib and erlotinib to placebo and erlotinib.

Complete data from the ATTENTION trial are expected in the second half of 2013. ArQule will discuss the further conduct of this trial at its previously announced third quarter fiscal 2012 conference call, scheduled for November 1, 2012 at 9:00 a.m. eastern time. Conference call-in information is as follows:

Conference Call Dial-In Numbers

Domestic:      (877) 868-1831
International: (914) 495-8595

A replay of the conference call will be available beginning approximately two hours after its completion for seven days and can be accessed by dialing toll-free 1-855-859-2056 and 1-404-537-3406 from outside the U.S. For archived calls, the access code is 53861797.

Forward Looking Statements

This Form 8-K contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified by the words "will," "expects," "anticipates," "believes," "estimates" or similar expressions. These forward-looking statements reflect management's view of future events and are subject to risks, uncertainties, assumptions and other important factors, many of which may be beyond our control, and could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Factors that could cause actual results to differ from such statements include, but are not limited to: an adverse decision or decisions following a review of additional safety information, or findings regarding a clinical benefit that are inconsistent with those of recent trials. The forward- looking statements contained herein represent management's judgment of ArQule as of the date hereof. We disclaim any intent or obligation to update any forward-looking statement except to the extent required by law.

  Add ARQL to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ARQL - All Recent SEC Filings
Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.